Oral administration of EOCW attenuates the histological changes associated to the progression and severity of bleomycin-induced pulmonary fibrosis in rodents, likely due to inhibition of TGF-β immunohistochemical expression and the consequent decrease in the myofibroblast differentiation. Here, TGFB1 is linked to pulmonary fibrosis.